Effect of Remimazolam Besylate combined with Sufentanil on the incidence of delirium in patients after cardiac surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038976

Enrollment

Unknown

Registered

2020-10-11

Start date

2021-01-01

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postcardiac surgery

Interventions

Group 1:Remimazolam Besylate combined with Sufentanil

Group 2:Propofol combined with Sufentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old; 2. Patients undergoing coronary artery bypass grafting, valve replacement or aortic dissection; 3. Patients who understand and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with cognitive impairment, history of mental illness, Alzheimer's disease and Parkinson's disease; 2. Patients who are unable to communicate due to severe audiovisual or language barriers; 3. Patients with recent history of epilepsy; 4. Recent alcoholism; 5. Patients with severe liver dysfunction (child Pugh grade C); 6. Patients with severe renal insufficiency (requiring renal replacement therapy); 7. Patients allergic to the study drug.

Design outcomes

Primary

Measure	Time frame
Incidence of delirium;	—

Secondary

Measure	Time frame
Time of delirium;Duration of delirium;ICU stay time;	—

Countries

China

Contacts

Public ContactSong Xuan

Liaocheng Cardiac Hospital

songxuan0303@163.com+86 17806359196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026